These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

545 related articles for article (PubMed ID: 20932621)

  • 1. An economic evaluation of erythropoiesis-stimulating agents in CKD.
    Clement FM; Klarenbach S; Tonelli M; Wiebe N; Hemmelgarn B; Manns BJ
    Am J Kidney Dis; 2010 Dec; 56(6):1050-61. PubMed ID: 20932621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD.
    Aspinall SL; Cunningham FE; Zhao X; Boresi JS; Tonnu-Mihara IQ; Smith KJ; Stone RA; Good CB;
    Am J Kidney Dis; 2012 Sep; 60(3):371-9. PubMed ID: 22633556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
    Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
    Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy.
    Foley RN; Curtis BM; Parfrey PS
    Clin J Am Soc Nephrol; 2008 Nov; 3(6):1669-75. PubMed ID: 18922988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of erythropoiesis-stimulating agents for anemia related to cancer.
    Klarenbach S; Manns B; Reiman T; Reaume MN; Lee H; Lloyd A; Wiebe N; Hemmelgarn B; Tonelli M
    Cancer; 2010 Jul; 116(13):3224-32. PubMed ID: 20564645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies.
    Wish JB; Coyne DW
    Mayo Clin Proc; 2007 Nov; 82(11):1371-80. PubMed ID: 17976358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.
    Johnson DW; Pascoe EM; Badve SV; Dalziel K; Cass A; Clarke P; Ferrari P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM;
    Am J Kidney Dis; 2015 Jan; 65(1):49-57. PubMed ID: 25115616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survey of attitude of physicians on updates in the management of anemia in chronic kidney disease patients.
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2009 May; 20(3):410-6. PubMed ID: 19414943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incremental cost effectiveness of pharmacist-managed erythropoiesis-stimulating agent clinics for non-dialysis-dependent chronic kidney disease patients.
    Aspinall SL; Smith KJ; Good CB; Zhao X; Stone RA; Tonnu-Mihara IQ; Cunningham FE
    Appl Health Econ Health Policy; 2013 Dec; 11(6):653-60. PubMed ID: 24092553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Regarding the optimal hemoglobin target range in renal anemia].
    Maurin N
    Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An economic evaluation of intravenous versus oral iron supplementation in people on haemodialysis.
    Wong G; Howard K; Hodson E; Irving M; Craig JC
    Nephrol Dial Transplant; 2013 Feb; 28(2):413-20. PubMed ID: 23182811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initiation of anaemia management in patients with chronic kidney disease not on dialysis in the Veterans Health Administration.
    Lawler EV; Gagnon DR; Fink J; Seliger S; Fonda J; Do TP; Gaziano JM; Bradbury BD
    Nephrol Dial Transplant; 2010 Jul; 25(7):2237-44. PubMed ID: 20083469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are there implications from the Trial to Reduce Cardiovascular Events with Aranesp Therapy study for anemia management in dialysis patients?
    Berns JS
    Curr Opin Nephrol Hypertens; 2010 Nov; 19(6):567-72. PubMed ID: 20601876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An expert opinion on the current treatment of anemia in patients with kidney disease.
    Locatelli F; Del Vecchio L
    Expert Opin Pharmacother; 2012 Mar; 13(4):495-503. PubMed ID: 22296648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietic response and outcomes in kidney disease and type 2 diabetes.
    Solomon SD; Uno H; Lewis EF; Eckardt KU; Lin J; Burdmann EA; de Zeeuw D; Ivanovich P; Levey AS; Parfrey P; Remuzzi G; Singh AK; Toto R; Huang F; Rossert J; McMurray JJ; Pfeffer MA;
    N Engl J Med; 2010 Sep; 363(12):1146-55. PubMed ID: 20843249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietic stimulating agents and quality of a patient's life: individualizing anemia treatment.
    Kliger AS; Fishbane S; Finkelstein FO
    Clin J Am Soc Nephrol; 2012 Feb; 7(2):354-7. PubMed ID: 22266571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
    Singh AK
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model.
    Crathorne L; Huxley N; Haasova M; Snowsill T; Jones-Hughes T; Hoyle M; Briscoe S; Coelho H; Long L; Medina-Lara A; Mujica-Mota R; Napier M; Hyde C
    Health Technol Assess; 2016 Feb; 20(13):1-588, v-vi. PubMed ID: 26907163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis.
    Naci H; de Lissovoy G; Hollenbeak C; Custer B; Hofmann A; McClellan W; Gitlin M
    J Med Econ; 2012; 15(2):293-304. PubMed ID: 22115328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.